The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease
- PMID: 30310479
- PMCID: PMC6159479
- DOI: 10.15420/ecr.2014.9.1.10
The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in western countries and is closely related to the metabolic syndrome. When NAFLD is associated with hepatocellular damage and inflammation (non-alcoholic steatohepatitis [NASH]) it can lead to severe liver disease. However, it has become clear that NAFLD is also associated with an increased risk of cardiovascular disease (CVD), independently of classical known risk factors for the latter. In the current review we briefly summarise the current clinical evidence on the role of NAFLD in CVD and discuss the potential mechanisms by which NAFLD can be linked to the pathophysiology of CVD.
Keywords: cardiovascular events; non-alcoholic fatty liver disease; pathophysiology; steatosis.
Conflict of interest statement
Disclosure: The author has no conflicts of interest to declare.
Figures
Similar articles
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
-
Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.J Clin Exp Hepatol. 2012 Jun;2(2):135-44. doi: 10.1016/S0973-6883(12)60102-9. Epub 2012 Jul 21. J Clin Exp Hepatol. 2012. PMID: 25755422 Free PMC article.
-
Nonalcoholic fatty liver disease and cardiovascular disease.Curr Pharm Des. 2014;20(14):2403-11. doi: 10.2174/13816128113199990476. Curr Pharm Des. 2014. PMID: 23844815 Review.
-
Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.Curr Vasc Pharmacol. 2018;16(3):246-253. doi: 10.2174/1570161115666170621082910. Curr Vasc Pharmacol. 2018. PMID: 28676019 Review.
-
Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.Eur Cardiol. 2024 May 9;19:e03. doi: 10.15420/ecr.2023.26. eCollection 2024. Eur Cardiol. 2024. PMID: 38807856 Free PMC article. Review.
Cited by
-
Effects of ω-3 PUFA-Rich Oil Supplementation on Cardiovascular Morphology and Aortic Vascular Reactivity of Adult Male Rats Submitted to an Hypercholesterolemic Diet.Biology (Basel). 2022 Jan 27;11(2):202. doi: 10.3390/biology11020202. Biology (Basel). 2022. PMID: 35205069 Free PMC article.
-
The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model.Pharmaceutics. 2021 Dec 27;14(1):45. doi: 10.3390/pharmaceutics14010045. Pharmaceutics. 2021. PMID: 35056941 Free PMC article.
-
Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease.Am J Hum Genet. 2021 Mar 4;108(3):411-430. doi: 10.1016/j.ajhg.2021.02.006. Epub 2021 Feb 23. Am J Hum Genet. 2021. PMID: 33626337 Free PMC article.
References
-
- Francque S. van Damme P, Van Herck K, Michielsen P . Chronic hepatitis and liver disease, Oxford Textbook of Public Health. 5th edition. Oxford: Oxford University Press; 2009. Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). pp. 1249–63.
-
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther. 2011;34(3):274–85. - PubMed
-
- Verrijken A, Francque S, Van Gaal L. The metabolic syndrome and the liver, Acta Gastroenterol Belg. 2008;71(1):48–59. - PubMed
-
- Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol. 1999;94(9):2467–74. - PubMed
-
- Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44. - PubMed
Publication types
LinkOut - more resources
Full Text Sources